

Erythromelalgia

[View the current Erythromelalgia InDepth page on BioPortfolio.com](#) (PDF)

(<http://www.bioportfolio.com/indepth/Erythromelalgia.html>) - Regularly Updated.

Erythromelalgia, also known as Mitchell's disease, red neuralgia, or erythermalgia, is a rare disorder in which blood vessels, usually in the lower extremities, are episodically blocked and inflamed. There is severe burning pain and skin redness associated with this blood vessel blockage. The attacks are periodic and are commonly triggered by heat, alcohol consumption, or exertion. Erythromelalgia can occur either as a primary or secondary disorder. Secondary erythromelalgia can result from small fiber peripheral neuropathy of any cause, hypercholesterolemia, mushroom or mercury poisoning, and some autoimmune disorders. Primary erythromelalgia is caused by mutation of the voltage-gated sodium channel α -subunit gene SCN9A. ([From the Wikipedia article Erythromelalgia.](#))



Recent Publications on Erythromelalgia:

- [Voltage-gated sodium channels: therapeutic targets for pain.](#)
*OBJECTIVE: To provide an overview of the role of voltage-gated sodium...*13th October, 2009
Department of Neurology and Center for Neuroscience and Regeneration- Pain Med. 2009 Oct;10(7):1260-9. ([DOI Direct Link](#))
- [Erythromelalgia mutation L823R shifts activation and inactivation of threshold sodium channel Nav1.7 to hyperpolarized potentials.](#)
*Erythromelalgia (also termed erythermalgia) is a neuropathic pain...*6th October, 2009
Department of Neurology, Yale University School of Medicine, New Haven, CT- Biochem Biophys Res Commun. 2009 Dec 11;390(2):319-24. Epub 2009 Oct 1. ([DOI Direct Link](#))
- [Experience with oral mexiletine in primary erythromelalgia in children.](#)
*Primary erythromelalgia is characterized by burning pain, redness, and...*10th September, 2009
Department of Pediatrics and Neonatology, Sher-i-Kashmir Institute of- Ann Saudi Med. 2009 Jul-Aug;29(4):316-8.
- [Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation.](#)
*Inherited erythromelalgia (IEM), an autosomal dominant disorder...*10th September, 2009
Department of Neurology, LCI 707, Yale University School of Medicine, 333- Brain. 2009 Jul;132(Pt 7):1711-22. Epub 2009 Apr 15. ([DOI Direct Link](#))
- [A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia.](#)
*OBJECTIVE: Human and animal studies have shown that Na(v)1.7 sodium...*13th August, 2009
Department of Neurology, Yale University School of Medicine, New Haven, CT- Ann Neurol. 2009 Jun;65(6):733-41. ([DOI Direct Link](#))
- [Patient education and self-advocacy: queries and responses on pain management; erythromelalgia.](#)
*Questions from patients concerning a disease process known as...*12th August, 2009
- J Pain Palliat Care Pharmacother. 2009 Sep;23(3):295-7. ([DOI Direct Link](#))
- [\[Primary erythermalgia: efficacy of oxcarbazepine\]](#)

- BACKGROUND: Essential erythromelgia is a rare acrosyndrome that is...*30th July, 2009
Service de dermatologie-venereologie, CHU Ibn Rochd, Casablanca, Maroc.- Ann Dermatol Venereol. 2009 Apr;136(4):337-40. Epub 2009 Feb 28. ([DOI Direct Link](#))
- [Alternative splicing of Na\(V\)1.7 exon 5 increases the impact of the painful PEPD mutant channel I1461T.](#)
*Alternative splicing is known to alter pharmacological sensitivities,...*28th July, 2009
Department of Pharmacology and Toxicology, Stark Neurosciences Research- Channels (Austin). 2009 Jul-Aug;3(4):259-67. Epub 2009 Jul 23.
 - [Macrovascular arteriovenous shunts \(MAS\): A newly identified structure in the abdominal wall with implications for thermoregulation and free tissue transfer.](#)
*Microscopic arteriovenous anastomoses are known structures that have many...*7th July, 2009
Jack Brockhoff Reconstructive Plastic Surgery Research Unit, Room E533,- J Plast Reconstr Aesthet Surg. 2009 Jul 2. ([DOI Direct Link](#))
 - [Treatment with carbamazepine and gabapentin of a patient with primary erythromelgia \(erythromelalgia\) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.](#)
*Summary Primary erythromelgia (erythromelalgia) is a rare autosomal...*25th June, 2009
Department of Dermatology, St George's Hospital, London, UK.- Clin Exp Dermatol. 2009 Jun 17. ([DOI Direct Link](#))
 - [Red ear syndrome and auricular erythromelalgia: the same condition?](#)
*Several cases of relapsing attacks during which the ear becomes red and...*6th June, 2009
Department of Dermatology, J.W. Goethe-University, Frankfurt, Germany.- Clin Exp Dermatol. 2009 Jun 1. ([DOI Direct Link](#))
 - [Genetics and molecular pathophysiology of Na\(v\)1.7-related pain syndromes.](#)
*SCN9A, the gene which encodes voltage-gated sodium channel Na(v)1.7, is...*6th June, 2009
Department of Neurology, Yale University School of Medicine, New Haven,- Adv Genet. 2008;63:85-110. ([DOI Direct Link](#))
 - [Romiplostim-induced erythromelalgia in a patient with idiopathic thrombocytopenic purpura.](#)
*Several cases of relapsing attacks during which the ear becomes red and...*3rd June, 2009
- Br J Dermatol. 2009 Aug;161(2):482-4. Epub 2009 May 26. ([DOI Direct Link](#))
 - [Microneurographic findings of relevance to pain in patients with erythromelalgia and patients with diabetic neuropathy.](#)
*Mechanisms responsible for neuropathic pain are still unclear. By using...*2nd June, 2009
Laboratory of Clinical Neurophysiology, Department of Neurology, Oslo- Neurosci Lett. 2009 May 28. ([DOI Direct Link](#))
 - [A case of primary erythromelalgia.](#)
*Inherited erythromelalgia (IEM), an autosomal dominant disorder...*17th April, 2009
- J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1338-9. Epub 2009 Apr 2. ([DOI Direct Link](#))

Erythromelalgia Patents:



- 7371825- [Anti-MCP-1 antibodies, compositions, methods and uses](#)
- 7452538- [Death domain containing receptor 4 antibodies and methods](#)
- 7456256- [BGS 4](#)
- 7456288- [Heterocyclic compounds and methods of making and using thereof](#)

- 7459531- [50 Human secreted proteins](#)
- 7459532- [Variants of the TRP channel family member, LTRPC3G](#)
- 7465707- [Methods of treatment with TR10 polypeptides](#)
- 7476384- [Death domain containing receptor 4 antibody and methods](#)
- 7482013- [Albumin fusion proteins](#)
- 7482334- [Therapeutic treatment methods](#)
- 7491391- [Anti-IL-23 antibodies, compositions, methods and uses](#)
- 7446176- [12 human secreted proteins](#)
- 7439241- [Compounds, formulations, and methods for treating or preventing rosacea](#)
- 7435808- [Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2](#)
- 7381722- [Tetracyclic amino and carboxamido compounds and methods of use thereof](#)
- 7381800- [Antibodies to HBIMF63 polypeptide](#)
- 7390637- [Keratinocyte derived interferon](#)
- 7393662- [Human EPO mimetic hinge core mimetibodies, compositions, methods and uses](#)
- 7393934- [Human G-protein chemokine receptor \(CCR5\) HDGNR10](#)
- 7402312- [Antibodies to vascular endothelial growth factor 2 \(VEGF-2\)](#)
- 7411051- [Antibodies to HDPPA04 polypeptide](#)
- 7425622- [Antibodies against C3a receptor](#)
- 7429575- [N-\(phosphonoalkyl\)-amino acids, derivatives thereof and compositions and methods of use](#)
- 7429646- [Antibodies to human tumor necrosis factor receptor-like 2](#)
- 7498027- [Methods of treatment using human tumor necrosis factor receptor TR17 antibodies](#)
- 7501123- [Human G-protein chemokine receptor \(CCR5\) HDGNR10](#)
- 7560112- [Anti-il-6 antibodies, compositions, methods and uses](#)
- 7560247- [Nucleic acids encoding anti-IL-12 antibodies, and methods of production](#)
- 7569384- [Albumin fusion proteins](#)
- 7572618- [Polynucleotides encoding novel PCSK9 variants](#)
- 7572776- [N-\(phosphonoalkyl\)-amino acids, derivatives thereof and compositions and methods of use](#)
- 7592010- [Albumin fusion proteins](#)
- 7595038- [Methods of treatment using antibodies to follistatin-3](#)
- 7597886- [Tumor necrosis factor-gamma](#)
- 7598348- [Adiponectin receptor variant, AdipoR2v2](#)
- 7605174- [Indane derivatives as modulators of ion channels](#)
- 7550569- [Antibodies that specifically bind to GMAD](#)
- 7550142- [Anti-integrin antibodies, compositions, methods and uses](#)
- 7547767- [Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses](#)
- 7504105- [Treatment using antibodies to cytokine receptor common gamma chain like](#)
- 7504481- [TRP channel family member, LTRPC3 polypeptides](#)
- 7507413- [Albumin fusion proteins](#)
- 7507414- [Albumin fusion proteins](#)
- 7511017- [Methods of treatment with TNFR5](#)
- 7514079- [Antibodies that specifically bind to neurokinin B](#)
- 7521206- [Anti-TNF antibodies, compositions, methods and uses](#)
- 7531310- [Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11](#)
- 7534428- [Antibodies to tumor necrosis factor receptors 6.alpha. and 6.beta.](#)
- 7547687- [Therapeutic treatment methods](#)
- 7612181- [Dual variable domain immunoglobulin and uses thereof](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

